FibroBiologics, Inc. (FBLG)
| Market Cap | 6.55M -61.1% |
| Revenue (ttm) | n/a |
| Net Income | -18.14M |
| EPS | -4.77 |
| Shares Out | 6.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,070 |
| Open | 0.9400 |
| Previous Close | 0.9567 |
| Day's Range | 0.9111 - 0.9712 |
| 52-Week Range | 0.6201 - 9.5980 |
| Beta | 1.84 |
| Analysts | Buy |
| Price Target | 12.50 (+1,226.96%) |
| Est. Earnings | Nov 17, 2026 |
About FBLG
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company’s product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, includi... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for FBLG stock is "Buy." The 12-month stock price target is $12.5, which is an increase of 1,226.96% from the latest price.
News
FibroBiologics granted European Patent No. EP 4454709
FibroBiologics (FBLG) announced that the European Patent Office has granted European Patent No. EP 4454709, titled “Fibroblast Delivery of Tumor Inhibitory Agents.” The patent covers methods of prepar...
FibroBiologics Announces Grant of European Patent for Fibroblast Delivery of Tumor Inhibitory Agents
Newly Granted Patent Covers Methods of Preparing Fibroblasts to Home to Tumors and Carry Oncolytic Viruses and Other Anti-Cancer Agents HOUSTON, Nov. 5, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasd...
FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting
FSdC Spheroids Preserved Disc Height Better Than Any Other Fibroblast-Based Approach Tested in a 12-Week Rabbit Model of Degenerative Disc Disease HOUSTON, Oct. 19, 2026 /PRNewswire/ -- FibroBiologics...
FibroBiologics’ patent application accepted in Australia
FibroBiologics (FBLG) announced that IP Australia has issued a Notice of Acceptance for Australian Patent Application No. 2024200985, titled “Cellular Blend for the Regeneration of Chondrocytes or Car...
FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs
Accepted Patent Contains Claims Covering Methods of Combining Fibroblasts, Platelet Rich Plasma, and Nucleus Pulposus Conditioned Media to Regenerate Cartilage and Improve the Condition of Degenerated...
FibroBiologics files U.S. patent application covering, GLP-1, other peptides
FibroBiologics (FBLG) announced that it has filed a U.S. patent application covering a new cell-based technology designed to continuously produce peptides such as GLP-1, GIP and GLP-2 inside the body.
FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body
New approach proposes an alternative to repeated injections HOUSTON, Oct. 7, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 27...
FibroBiologics announces grant of European patent
FibroBiologics (FBLG) announced that the European Patent Office has granted European Patent No. 3568465, titled “Methods of Enhancing Fibroblast Therapeutic Activity.” The patent covers methods of aug...
FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity
Newly Granted Patent Covers Methods of Augmenting the Regenerative Efficacy of Fibroblasts Using Platelet Rich Plasma and Cytokines, with Claims Directed to Angiogenesis and Spinal Disc Regeneration H...
FibroBiologics Transcript: Investor update
The DFU phase I/II trial is enrolling, with six-week interim data expected before year-end; the psoriasis IND is filed and an MS IND is planned before year-end. Management cited $3.5 million in prior-quarter cash and runway through interim results.
FibroBiologics Transcript: EGM 2026
Shareholders approved the issuance of new shares related to outstanding warrants. Updates included clinical progress in wound care and psoriasis, new board appointments, and a robust pipeline targeting chronic diseases. No questions were raised during the meeting.
FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer
HOUSTON, Sept. 17, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focu...
FibroBiologics Slides: Corporate presentation
FibroBiologics has posted slides in relation to its latest quarterly earnings report, which was published on September 17, 2026.
FibroBiologics Proxy statement: Proxy filing
FibroBiologics filed a proxy statement on September 9, 2026, providing details for shareholder voting and corporate governance matters.
FibroBiologics announces USPTO issued patent on use of fibroblasts
FibroBiologics (FBLG) announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,721,866, titled “Therapeutic Use of Fibroblasts for Use in Wound Healing.” The ...
FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing
Newly Issued Patent Covers Topical Administration of 3D Spheroid Fibroblasts and Fibroblast-Derived Materials to Treat and Accelerate the Healing of Wounds HOUSTON, Sept. 3, 2026 /PRNewswire/ -- Fibro...
FibroBiologics announces USPTO issued patent for Fibroblast Conditioned Media
FibroBiologics (FBLG) announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,716,055, titled “Treatment of Disc Degenerative Disease and Stimulation of Prot...
FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media
Newly Issued Patent Covers Methods of Promoting Disc Regeneration Using Components Derived from Stimulated Fibroblasts HOUSTON, Sept. 1, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("Fibr...
FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
HOUSTON, Aug. 27, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus...
FibroBiologics Regains Compliance with Nasdaq Trading Rules
HOUSTON, Aug. 26, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus...
FibroBiologics Appoints Leigh Steinberg to Board of Directors
Legendary Sports Agent, Attorney, and Longtime Advocate for Human Longevity and Brain Health Joins Board HOUSTON, Aug. 24, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), ...
FibroBiologics says Australian patent accepted for Cannabidiol Adjuvant Therapy
FibroBiologics (FBLG) announced the acceptance by IP Australia of Australian Patent Application No. 2020368344, entitled “Cannabidiol Adjuvant Therapy for Treatment of Disc Degenerative Disease.” The ...
FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease
Patent covers the use of cannabidiol in combination with fibroblast-based cell therapy to treat degenerative disc disease HOUSTON, Aug. 20, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("F...
FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints
Animal trials show cartilage repair within four weeks following a single injection of chondrocyte spheroids HOUSTON, Aug. 18, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"...
FibroBiologics awarded new patent from USPTO
FibroBiologics (FBLG) announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,691,147, entitled “Methods and Compositions for Treatment of Type 1 Diabetes Using Fibr...